Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20042867 | 0.88 | PROKR1 (0.39) | PROKR1SMN1; SMN2RAB9AKDM4ECYP11B1 | |
| SCHEMBL20042742 | 0.84 | PROKR1 (0.35) | PROKR1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL20042844 | 0.82 | P2RX7 (0.33) | SMN1; SMN2KDM4EPIK3CD | |
| SCHEMBL20042958 | 0.82 | TACR3 (0.42) | — | |
| SCHEMBL20042982 | 0.82 | P2RX7 (0.46) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL20042851 | 0.82 | P2RX7 (0.46) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL20042865 | 0.82 | TACR3 (0.42) | — | |
| SCHEMBL20042766 | 0.80 | TACR3 (0.36) | SMN1; SMN2KDM4E | |
| SCHEMBL20042896 | 0.80 | GRM5 (0.38) | LMNA | |
| SCHEMBL20042868 | 0.79 | P2RX7 (0.35) | SMN1; SMN2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018066718-A1 | THERAPEUTIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-12 | — | — | WO | disclosed |